## 117TH CONGRESS 2D SESSION

## H. R. 9489

To direct the Secretary of Energy to establish a National Laboratory Biotechnology Program to address biotechnology threats, and for other purposes.

## IN THE HOUSE OF REPRESENTATIVES

December 12, 2022

Mr. Foster (for himself and Ms. Leger Fernandez) introduced the following bill; which was referred to the Committee on Science, Space, and Technology, and in addition to the Committees on Armed Services, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

## A BILL

To direct the Secretary of Energy to establish a National Laboratory Biotechnology Program to address biotechnology threats, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "National Laboratory
- 5 Biotechnology Research Act of 2022".
- 6 SEC. 2. DEFINITIONS.
- 7 In this Act:

1	(1) Department.—The term "Department"
2	means the Department of Energy.
3	(2) National Laboratory.—The term "Na-
4	tional Laboratory" has the meaning given the term
5	in section 2 of the Energy Policy Act of 2005 (42
6	U.S.C. 15801).
7	(3) NNSA.—The term "NNSA" means the Na
8	tional Nuclear Security Administration.
9	(4) Office.—The term "Office" means the
10	joint program office established under section 3(b)
11	(5) Office of intelligence and counter-
12	INTELLIGENCE.—The term "Office of Intelligence
13	and Counterintelligence" means the Office of Intel-
14	ligence and Counterintelligence of the Department.
15	(6) Office of Science.—The term "Office of
16	Science" means the Office of Science of the Depart
17	ment.
18	(7) Program.—The term "Program" means
19	the National Laboratory Biotechnology Program es-
20	tablished under section 3(a).
21	(8) Secretary.—The term "Secretary" means
22	the Secretary of Energy.

1	SEC. 3. NATIONAL LABORATORY BIOTECHNOLOGY PRO-
2	GRAM.
3	(a) In General.—The Secretary shall establish a
4	National Laboratory Biotechnology Program to integrate
5	the resources of the Department, including the Office of
6	Science, the Office of Intelligence and Counterintelligence,
7	and the NNSA, to provide research, development, test and
8	evaluation, and response capabilities to respond to—
9	(1) long-term biotechnology threats facing the
10	United States; and
11	(2) any remaining threats posed by COVID-19.
12	(b) Joint Program Office.—To carry out the Pro-
13	gram, the Secretary shall establish a joint program office,
14	which shall comprise appropriate leadership from the Of-
15	fice of Science, the NNSA, and the National Laboratories.
16	(c) Functions.—The Office shall—
17	(1) oversee the development and operation of
18	major research activities of the Program;
19	(2) periodically review and recommend updates
20	as necessary to Program policies and guidelines for
21	the development and operation of major research ac-
22	tivities;
23	(3) collaborate with the directors of research di-
24	rectorates of the Department, directors of National
25	Laboratories, and other senior Department officials,
26	as appropriate, to gain greater access to top re-

1	searchers and new and potentially transformative
2	ideas;
3	(4) enable access to broad scientific and tech-
4	nical expertise and resources that will lead to the de-
5	ployment of innovative products, including
6	through—
7	(A) research and development, including
8	proof of concept, technical development, and
9	compliance testing activities; and
10	(B) early-stage product development, in-
11	cluding through—
12	(i) computational modeling and sim-
13	ulation;
14	(ii) molecular structural determina-
15	tion;
16	(iii) genomic sequencing;
17	(iv) epidemiological and logistics sup-
18	port;
19	(v) knowledge discovery infrastructure
20	and scalable protected data;
21	(vi) advanced manufacturing to ad-
22	dress supply chain bottlenecks;
23	(vii) new capabilities for testing of
24	clinical and nonclinical samples:

1	(viii) understanding environmental
2	fate and transport of viruses; and
3	(ix) discovery of potential therapeutics
4	through computation and molecular struc-
5	ture determination;
6	(5) provide access to user facilities with ad-
7	vanced or unique equipment, services, materials, and
8	other resources to perform research and testing;
9	(6) support technology transfer and related ac-
10	tivities; and
11	(7) promote access and development across the
12	Federal Government and to United States industry,
13	including startup companies, of early applications of
14	the technologies, innovations, and expertise bene-
15	ficial to the public that are derived from Program
16	activities.
17	(d) Biodefense Expertise.—
18	(1) In general.—In carrying out the Pro-
19	gram, the Office shall support research that har-
20	nesses the capabilities of the National Laboratories
21	to address advanced biological threats of national se-
22	curity significance through assessments and research
23	and development programs that—
24	(A) support the near- and long-term bio-
25	defense needs of the United States;

1	(B) support the national security commu-
2	nity in reducing uncertainty and risk;
3	(C) enable greater access to top research-
4	ers and new and potentially transformative
5	ideas for biodefense of human, animal, plant,
6	environment, and infrastructure assets (includ-
7	ing physical, cyber, and economic infrastruc-
8	ture); and
9	(D) enable access to broad scientific and
10	technical expertise and resources that will lead
11	to the development and deployment of innova-
12	tive biodefense assessments and solutions, in-
13	cluding through—
14	(i) the accessing, monitoring, and
15	evaluation of biological threats to reduce
16	risk, including through analysis and
17	prioritization of gaps and vulnerabilities
18	across open-source and classified data;
19	(ii) development of scientific and tech-
20	nical roadmaps—
21	(I) to address gaps and vulnera-
22	bilities;
23	(II) to inform analyses of tech-
24	nologies; and

1	(III) to accelerate the application
2	of unclassified research to classified
3	applications; and
4	(iii) demonstration activities to enable
5	deployment, including—
6	(I) threat signature development
7	and validation;
8	(II) automated anomaly detection
9	using artificial intelligence and ma-
10	chine learning;
11	(III) fate and transport dynamics
12	for priority scenarios;
13	(IV) data curation, access, stor-
14	age, and security at scale; and
15	(V) risk assessment tools.
16	(2) RESOURCES.—The Secretary shall ensure
17	that the Office is provided and uses sufficient re-
18	sources to carry out paragraph (1).
19	(e) Strengthening Institutional Research
20	AND PRIVATE PARTNERSHIPS.—
21	(1) In General.—The Office shall, to the max-
22	imum extent practicable, promote cooperative re-
23	search and development activities under the Pro-
24	gram, including collaboration between appropriate

- industry and academic institutions to promote inno-vation and knowledge creation.
  - (2) Accessibility of information.—The Office shall develop, maintain, and publicize information on scientific user facilities and capabilities supported by laboratories of the Department for combating biotechnology threats, which shall be accessible for use by individuals from academic institutions and industry.
    - (3) ACADEMIC PARTICIPATION.—The Office shall, to the maximum extent practicable—
      - (A) conduct outreach about internship opportunities relating to activities under the Program primarily to institutions of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) and minority-serving institutions of higher education;
      - (B) encourage the development of research collaborations between research-intensive universities and the institutions described in subparagraph (A); and
      - (C) provide traineeships at the institutions described in subparagraph (A) to graduate students who pursue a masters or doctoral degree

1	in an academic field relevant to research ad-
2	vanced under the Program.
3	(f) EVALUATION AND PLAN.—
4	(1) In general.—Not less frequently than bi-
5	ennially, the Secretary shall—
6	(A) evaluate the activities carried out
7	under the Program; and
8	(B) develop a strategic research plan under
9	the Program, which shall be made publicly
10	available and submitted to the Committee on
11	Energy and Natural Resources of the Senate
12	and the Committee on Energy and Commerce
13	of the House of Representatives.
14	(2) Classified information.—If the stra-
15	tegic research plan developed under paragraph
16	(1)(B) contains classified information, the plan—
17	(A) shall be made publicly available and
18	submitted to the committees of Congress de-
19	scribed in paragraph (1)(B) in an unclassified
20	format; and
21	(B) may, as part of the submission to
22	those committees of Congress only, include a
23	classified annex containing any sensitive or clas-
24	sified information, as necessary.

1 INTERAGENCY COLLABORATION.—The Office may collaborate with the Secretary of Homeland Security, the Secretary of Health and Human Services, the Sec-3 4 retary of Defense, and the heads of other appropriate Fed-5 eral departments and agencies to advance biotechnology 6 research and development under the Program. 7 (h) AUTHORIZATION OF APPROPRIATIONS.—There are authorized to be appropriated to the Secretary to carry 8 9 out this section, to remain available until expended— 10 (1) \$30,000,000 for fiscal year 2023; 11 (2) \$40,000,000 for fiscal year 2024; 12 (3) \$45,000,000 for fiscal year 2025; and (4) \$50,000,000 for each of fiscal years 2026 13

 $\bigcirc$ 

14

and 2027.